• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 10:30:26 AM ET
    $ABMD
    Medical/Dental Instruments
    Health Care
    Get the next $ABMD alert in real time by email
    SC 13G/A 1 tv0112-abiomedinc.htm SCHEDULE 13G/A abiomedinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  ABIOMED Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  003654100

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  003654100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    77,552

    7.  SOLE DISPOSITIVE POWER

    4,601,404

    8.  SHARED DISPOSITIVE POWER

    200,355

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,801,759

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.63%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    ABIOMED Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    22 Cherry Hill Drive
    Danvers, MA 01923

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    003654100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    4,801,759

      (b) Percent of Class:

    10.63%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  77,552

    (iii)  sole power to dispose of or to direct the disposition of:  4,601,404

    (iv)  shared power to dispose or to direct the disposition of:  200,355

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $ABMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABMD

    DatePrice TargetRatingAnalyst
    11/2/2022$235.00 → $380.00Underweight → Equal-Weight
    Morgan Stanley
    11/2/2022$355.00 → $388.00Buy → Hold
    Deutsche Bank
    10/13/2022$300.00Buy
    Mizuho
    4/6/2022$330.00Peer Perform
    Wolfe Research
    2/4/2022$292.00 → $275.00Underweight
    Morgan Stanley
    2/4/2022$345.00 → $325.00Market Perform
    SVB Leerink
    1/7/2022$269.00 → $292.00Underweight
    Morgan Stanley
    8/6/2021$335.00 → $375.00Market Perform
    SVB Leerink
    More analyst ratings

    $ABMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

      Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

      7/12/23 9:00:00 AM ET
      $STIM
      $ABMD
      Medical/Dental Instruments
      Health Care
    • FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

      Abiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI). This press release features multimedia. View the full release here: htt

      12/21/22 9:00:00 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400

      NEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector December 22, 2022 S&P 500 Addition Steel Dynamics STLD Materials S&P 500 Deletion

      12/19/22 6:35:00 PM ET
      $ABMD
      $JNJ
      $SMCI
      $SPGI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Manufacturing

    $ABMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

      Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

      7/12/23 9:00:00 AM ET
      $STIM
      $ABMD
      Medical/Dental Instruments
      Health Care
    • MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

      Succeeds Derek Herrera after two-year term Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies. This announcement is being made today during the Plenary Luncheon at AdvaMed's MedTech Conference 2022, which is taking place through Oct. 26 at the Boston Convention and Exhibition Center. A U.S. Army combat Veteran, Sutherland succeeds Derek Herrera and will assume the role on January 1, 2023. This press release features multimedia. View the full release here: https

      10/24/22 12:00:00 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Dr. Paula A. Johnson Joins Abiomed Board of Directors

      Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005332/en/Dr. Paula A. Johnson joins the Abiomed Board of Directors (Photo: Business Wire) "Dr. Johnson is known internationally as a leading expert in healthcare, medical research and health policy, especially for her work advancing the health of women," said Michae

      4/28/21 8:03:00 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)

      SC 13G/A - ABIOMED INC (0000815094) (Subject)

      1/6/23 6:39:54 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by ABIOMED Inc.

      SC 13G - ABIOMED INC (0000815094) (Subject)

      12/29/22 4:03:01 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)

      SC 13G/A - ABIOMED INC (0000815094) (Subject)

      2/9/22 3:16:00 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sutter Martin P returned 123,370 shares to the company, closing all direct ownership in the company

      4 - ABIOMED INC (0000815094) (Issuer)

      12/27/22 8:47:48 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Puhy Dorothy E returned 14,590 shares to the company, closing all direct ownership in the company

      4 - ABIOMED INC (0000815094) (Issuer)

      12/27/22 8:44:35 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Trapp Todd A returned 14,166 shares to the company, closing all direct ownership in the company

      4 - ABIOMED INC (0000815094) (Issuer)

      12/27/22 8:41:11 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abiomed upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Abiomed from Underweight to Equal-Weight and set a new price target of $380.00 from $235.00 previously

      11/2/22 9:11:07 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Abiomed downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Abiomed from Buy to Hold and set a new price target of $388.00 from $355.00 previously

      11/2/22 6:09:28 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Abiomed with a new price target

      Mizuho initiated coverage of Abiomed with a rating of Buy and set a new price target of $300.00

      10/13/22 7:17:59 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Financials

    Live finance-specific insights

    See more
    • Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

      ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa

      11/1/22 7:00:00 AM ET
      $ABMD
      $JNJ
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Johnson & Johnson to Acquire Abiomed

      Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil

      11/1/22 6:30:00 AM ET
      $ABMD
      $JNJ
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

      Abiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Tuesday, November 1, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/493387843 or dial (844) 200-6205; the international number is (929) 526-1599 access code 367357. A replay of this conference call will be available until Tuesday, November 8, 2022. The repla

      10/13/22 7:00:00 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    SEC Filings

    See more
    • SEC Form 15-12G filed by ABIOMED Inc.

      15-12G - ABIOMED INC (0000815094) (Filer)

      1/3/23 8:30:58 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by ABIOMED Inc.

      S-8 POS - ABIOMED INC (0000815094) (Filer)

      12/22/22 4:46:31 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by ABIOMED Inc.

      S-8 POS - ABIOMED INC (0000815094) (Filer)

      12/22/22 4:46:02 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care